Search Results

1 - 2 of 2 items :

  • management measures x
Clear All
Clinical, Hormonal, and Ultrasound Characteristics of Patients with Newly Diagnosed Graves’ Disease And Different Thyroid Antibody Profiles

REFERENCES 1. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421. 2. Tun NN, Beckett G, Zammitt NN, et al. Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ Disease relapse. Thyroid 2016; 26: 1004-1009. 3. Sahlmann CO, Siefker U, Lehmann K, et al. Quantitative thyroid scintigraphy for the differentiation of Graves’ disease and hyperthyroid autoimmune thyroiditis

Open access
Hypertrophic Scars and Keloids – Contemporary Concepts and Treatment Options

, № 6, 1841-1852. 29. Chodon , T. et al. Keloid-derived fi broblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. - Am. J. Pathol., 157, 2000, № 5, 1661-1669. 30. Mustoe , T. A. et al. International clinical recommendations on scar management. - Plast. Reconstr. Surg., 110, 2002, № 2, 560-571. 31. Reish , R. G. et E. Eriksson. Scars: a review of emerging and currently available therapies. - Plast. Reconstr. Surg., 122, 2008, № 4

Open access